Navigation Links
NeoStrata(R) Announces the Launch of PSORENT(TM) Psoriasis Topical Treatment

PSORENT Features a Unique and Innovative Formulation Available Without a

Prescription Through Physicians

PRINCETON, N.J., Feb. 4 /PRNewswire/ -- NeoStrata today announced the launch of PSORENT, a clinically proven, steroid-free, topical treatment for psoriasis. PSORENT contains LCD (liquid carbonis distillate), which has proven efficacy against psoriasis symptoms, in a novel, aesthetically advanced formulation and package that promotes high patient compliance. PSORENT is available without a prescription from dermatologists beginning March 2008.

"With the launch of PSORENT, physicians will be able to offer patients a novel psoriasis treatment that reduces the unpleasant aspects of traditional coal tar therapy, resulting in high patient compliance without compromising efficacy or safety," said Barbara Green, Vice President for Technology and Clinical Affairs at NeoStrata. "PSORENT's effective and unique fast-absorbing solution applies easily and conveniently making it an ideal first-line therapy for the vast majority of psoriasis patients."

PSORENT is an aesthetically advanced, fast absorbing topical coal tar solution that provides a new alternative for psoriasis patients and providers. Optimally formulated with a 15 percent concentration of LCD, the therapeutic equivalent of 2.3 percent coal tar, PSORENT is an innovative topical solution to treat the chronic redness and scaling associated with psoriasis. PSORENT is supplied in a convenient dab-on delivery system that speeds LCD absorption and avoids the stains, odor and mess that are typically associated with coal tar treatments. Additionally, the dab-on applicator allows the patient to apply PSORENT directly to the affected areas without touching either the solution or the skin, resulting in a highly effective and easy to use treatment. PSORENT is available only through physicians' offices. One 100mL bottle provides up to a 3-month supply, at a suggested retail price of $45.00, making it a cost effective alternative to prescription medications which may or may not be covered by health insurance.

Psoriasis is an immune-mediated, genetic disease manifesting in the skin and/or the joints. According to the National Institutes of Health, as many as 7.5 million Americans have psoriasis. The National Psoriasis Foundation defines mild psoriasis as affecting less than three percent of the body; three percent to 10 percent is considered moderate; more than 10 percent is considered severe. According to the National Psoriasis Foundation's Benchmark Survey on Psoriasis and Psoriatic Arthritis, the disease is not merely a cosmetic problem. Nearly 60 percent reported their psoriasis to be a large problem in their everyday life. The survey also indicates that psoriasis had a greater impact on quality of life in women and younger patients.

About NeoStrata

The NeoStrata Company, located in Princeton, NJ, develops and markets advanced therapeutic and cosmetic dermatological products through consumer outlets and physicians' offices in the United States and internationally through physicians' offices, pharmacies and spas.

SOURCE The NeoStrata Company
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
(Date:11/24/2015)... 2015 --> ... "Oligonucleotide Synthesis Market by Product & Services (Primer, Probe, ... DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) ... market is expected to reach USD 1,918.6 Million by ... CAGR of 10.1% during the forecast period. ...
(Date:11/24/2015)... 24, 2015 SHPG ) announced today that ... Piper Jaffray 27 th Annual Healthcare Conference in ... at 8:30 a.m. EST (1:30 p.m. GMT). --> SHPG ... will participate in the Piper Jaffray 27 th Annual Healthcare ... Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ...
(Date:11/24/2015)... CITY , Nov. 24, 2015 /PRNewswire/ - ... "Company") announced today that the remaining 11,000 post-share ... Share Purchase Warrants (the "Series B Warrants") subject ... were exercised on November 23, 2015, which will ... Shares.  After giving effect to the issuance of ...
(Date:11/24/2015)... ... November 24, 2015 , ... InSphero AG, the leading supplier of ... has promoted Melanie Aregger to serve as Chief Operating Officer. , Having ... management team and was promoted to Head of InSphero Diagnostics in 2014. ...
Breaking Biology Technology:
(Date:11/19/2015)... -- Although some 350 companies are actively involved in molecular ... according to Kalorama Information. These include Roche Diagnostics, Hologic, Abbott ... of the 6.1 billion-dollar molecular testing market, according to ... Diagnostic s .    ... one company and only a handful of companies can ...
(Date:11/17/2015)... Paris , qui ... Paris , qui s,est tenu du ... leader de l,innovation biométrique, a inventé le premier scanner ... sur la même surface de balayage. Jusqu,ici, deux scanners ... les empreintes digitales. Désormais, un seul scanner est en ...
(Date:11/12/2015)... 2015  A golden retriever that stayed healthy despite ... has provided a new lead for treating this muscle-wasting ... Institute of MIT and Harvard and the University of ... Cell, pinpoints a protective gene that ... effects. The Boston Children,s lab of Lou Kunkel ...
Breaking Biology News(10 mins):